<DOC>
	<DOCNO>NCT02407678</DOCNO>
	<brief_summary>The assessment efficacy ( respect preservation visual function retinal structure ) safety single subretinal injection AAV2.REP1 participant confirm diagnosis choroideremia , evaluate various functional anatomical outcome measure number time point 24 month post-treatment .</brief_summary>
	<brief_title>REP1 Gene Replacement Therapy Choroideremia</brief_title>
	<detailed_description />
	<mesh_term>Choroideremia</mesh_term>
	<criteria>1 . Candidate willing able give inform consent participation study . 2 . Male age 18 year . 3 . Genetic molecular confirm diagnosis choroideremia ( REP1 protein deficiency ) . 4 . Active disease visible clinically within macula region . 5 . Best correct visual acuity equal worse 6/6 ( 20/20 ; Decimal 1.0 ; LogMAR 0 ) good equal 6/60 ( 20/200 ; Decimal 0.1 ; LogMAR 1.0 ) study eye . 1 . Any female , male age 18 year . 2 . An additional cause sight loss ( e.g . amblyopia ) eye treat . 3 . Any significant ocular nonocular disease disorder , opinion investigator , may put participant risk participation study . 4 . Inability take systemic prednisolone minimum 3 week . 5 . Unwillingness use barrier contraception method period three month follow gene therapy surgery . 6 . Participation another research study involve investigational product precede 12 week .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>